A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration

Patients receiving a variety of chemotherapy regimens often develop chemotherapy‐induced anemia (CIA), which contributes to poor outcomes including increased mortality. Prompt and effective treatment of CIA is essential to prevent fewer chemotherapy dose delays and reductions. Optimal therapy of CIA is controversial and involves the solitary and combined use of intravenous iron, red blood cell (RBC) transfusions, and erythropoietin stimulating agents (ESAs). Despite the baseline coagulopathies present in patients with malignancy, administration of both RBC transfusions and ESAs is associated with venous thromboembolism (VTE). It remains unknown whether the risk of VTE in patients with CIA is greater among patients who receive RBC transfusions or ESAs.

• Publication year

  2020

• Venue

  eJHaem

• Publication date

  2020-05-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jha2.18PMID 35847693PMCID 9175772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration

  2020cited by this paper
• A retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent (ESA) administration.

  2019cited by this paper
• Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.

  2019cited by this paper
• Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization

  2018cited by this paper
• Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression

  2017cited by this paper
• Continued decline in blood collection and transfusion in the United States–2015

  2017cited by this paper
• Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests

  2017cited by this paper
• Anaemia in cancer patients — Expert Group recommendations

  2017cited by this paper
• Mechanisms and risk factors of thrombosis in cancer.

  2017cited by this paper
• The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort

  2017cited by this paper
• Supplemental findings from the National Blood Collection and Utilization Surveys, 2013 and 2015

  2017cited by this paper
• Understanding Venous Thromboembolism in Patients with Cancer

  2016cited by this paper
• Risk of thrombosis in cancer and the role of supportive care (transfusion, catheters, and growth factors).

  2016cited by this paper
• Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.

  2016influential reference
• Risk of Venous Thromboembolism in Multiple Myeloma: Identification of Risk Factor

  2016cited by this paper
• Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data

  2015cited by this paper
• Epidemiology of cancer-associated venous thrombosis.

  2013cited by this paper
• Cancer-associated thrombosis.

  2013cited by this paper
• Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation

  2013cited by this paper
• Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron

  2012cited by this paper
• A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score

  2012cited by this paper
• Association of blood transfusion and venous thromboembolism after colorectal cancer resection.

  2012cited by this paper
• Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.

  2012cited by this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2012cited by this paper
• High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.

  2011cited by this paper
• Complications associated with erythropoietin‐stimulating agents in patients with metastatic breast cancer

  2011cited by this paper
• Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors

  2011cited by this paper
• Prediction of venous thromboembolism in cancer patients.

  2010cited by this paper
• Thromboembolic Events in Patients With Colorectal Cancer Receiving the Combination of Bevacizumab-Based Chemotherapy and Erythropoietin Stimulating Agents

  2010cited by this paper
• Complications associated with erythropoietin stimulating agents (ESAs) in patients with metastatic breast cancer: A surveillance, epidemiology, and end results (SEER)-Medicare study.

  2009cited by this paper
• Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study.

  2009cited by this paper
• Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer

  2008cited by this paper
• Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer.

  2008cited by this paper
• Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study

  2008cited by this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cited by this paper
• Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

  2007cited by this paper
• Guideline : Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

  2007cited by this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006cited by this paper
• Chemotherapy-induced thrombosis.

  2006cited by this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2006cited by this paper
• Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

  2006cited by this paper
• Proinflammatory, immunomodulating, and prothrombotic properties of anemia and red blood cell transfusions

  2006cited by this paper
• Drug-related thrombosis in hematologic malignancies.

  2004cited by this paper
• The evolving role of epoetin alfa in cancer therapy.

  2004cited by this paper
• Transfusion issues in the cancer patient.

  2003cited by this paper

• Outcomes of the use of epoetin alfa in preoperative therapy of malignant tumors of the female reproductive system: analysis of a series of clinical cases

  2025cites this paper
• The impact of erythropoiesis-stimulating agent therapy on survival outcomes in patients with anemia associated with metastatic malignancies (a systematic review and meta-analysis)

  2025cites this paper
• Lung Cancer Related Thrombosis (LCART): Focus on Immune Checkpoint Blockade

  2024cites this paper
• Thromboembolic Risk in Prostate Cancer Patients Treated with PARP Inhibitors: A Systematic Review and Meta-analysis.

  2024cites this paper
• A retrospective analysis of venous thromboembolism trends in chemotherapy‐induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration

  2020cites this paper